 |
|
|
| |
A Phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Paul Kwo,1 Norman Gitlin,2 Ronald Nahass,3 David Bernstein,4 Sergio Rojter,5 Eugene Schiff,6 Mitchell Davis,7 Peter J. Ruane,8 Ziad Younes,9 Ronald Kalmeijer,10 Monika Peeters,11 Oliver Lenz,11 Bart Fevery,11 Guy De La Rosa,12 Jane Scott,13 Rekha Sinha,10 James Witek10
1Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University, Indianapolis, IN, USA; 2Atlanta Gastroenterology Specialists, Atlanta, GA, USA; 3ID Care, Hillsborough, NJ, USA; 4Hofstra North Shore Long Island Jewish School of Medicine, Manhasset, NY, USA; 5National Research Institute, Los Angeles, CA, USA; 6University of Miami Schiff Center for Liver Disease, Miami, FL, USA; 7Digestive CARE-South Florida Center of Gastroenterology, West Palm Beach, FL, USA; 8Ruane Medical and Liver Health Institute, Los Angeles, CA, USA; 9GASTRO ONE, Germantown, TN, USA; 10Janssen Research and Development, LLC, Titusville, NJ, USA; 11Janssen Infectious Diseases BVBA, Beerse, Belgium; 12Janssen Global Services, LLC, Titusville, NJ, USA; 13Janssen Global Services, LLC, High Wycombe, United Kingdom
|
| |
|
|
|
|
|
